Filing Flows › Protagonist Therapeutics (PTGX) › R&D spending
Protagonist Therapeutics (PTGX) R&D spending by quarter
Protagonist Therapeutics' R&D spending was $41.3M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $35.9M (Q1 2025) to $46.7M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $41.3M | -2% | +3% |
| Q2 2026 | $42.1M | -10% | +14% |
| Q1 2026 | $46.7M | +0.8% | +30% |
| Q4 2025 | $46.4M | +16% | — |
| Q3 2025 | $40.0M | +8% | — |
| Q2 2025 | $37.0M | +3% | — |
| Q1 2025 | $35.9M | — | — |
Q3 2026 at a glance
Protagonist Therapeutics, Q3 2026: revenue $274M (58× year over year), operating margin 79.6%, net earnings $220M, operating cash flow −$23.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protagonist Therapeutics' R&D spending?
Protagonist Therapeutics' R&D spending was $41.3M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has Protagonist Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $35.9M (Q1 2025) to $46.7M (Q1 2026).
Q3 2026 results → · How Protagonist Therapeutics makes money →